Q: Hi there, just looking for further clarification on PLI, have you assessed the risks in Prometic not receiving approval for the Plasminogen BLA from the FDA? Could it be possible that PLI raised further funds very quickly, at a substantial discount, at $1.70, trading well over $2 at that time, suspecting they will not be approved?
"The Corporation is responding diligently to all FDA requests in relation to the BLA review. The Corporation will provide further updates on the expected timeline of regulatory approval as soon as available"
Could it be possible that PLI is suspecting the FDA is looking for further clinical data for approval, which could take an additional 12 to 18 months for final approval? Have you assessed these types of risks in your modelling for the Growth Portfolio holding? Where do you see the stock price trading at, if the above scenario does occur?
Hope I am wrong above!
Thanks!
"The Corporation is responding diligently to all FDA requests in relation to the BLA review. The Corporation will provide further updates on the expected timeline of regulatory approval as soon as available"
Could it be possible that PLI is suspecting the FDA is looking for further clinical data for approval, which could take an additional 12 to 18 months for final approval? Have you assessed these types of risks in your modelling for the Growth Portfolio holding? Where do you see the stock price trading at, if the above scenario does occur?
Hope I am wrong above!
Thanks!